In-silico trial of intracranial flow diverters replicates and expands insights from conventional clinical trials.

ABSTRACT: The cost of clinical trials is ever-increasing. In-silico trials rely on virtual populations and interventions simulated using patient-specific models and may offer a solution to lower these costs. We present the flow diverter performance assessment (FD-PASS) in-silico trial, which models the treatment of intracranial aneurysms in 164 virtual patients with 82 distinct anatomies with a flow-diverting stent, using computational fluid dynamics to quantify post-treatment flow reduction. The predicted FD-PASS flow-diversion success rates replicate the values previously reported in three clinical trials. The in-silico approach allows broader investigation of factors associated with insufficient flow reduction than feasible in a conventional trial. Our findings demonstrate that in-silico trials o

SUBMITTER: Sarrami-Foroushani A 

PROVIDER: S-EPMC8222326 | biostudies-literature | 2021 Jun

REPOSITORIES: biostudies-literature